Citalopram updated on 07-01-2025

ADHD (Attention deficit hyperactivity disorder): Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14998
R61388		 Olstad - (Es)citalopram (Controls unexposed, disease free), 2023 Attention deficit hyperactivity disorder (ADHD) assessment - CBCL-DSM (ADHD subscale)— 5 years during pregnancy (anytime or not specified) population based cohort propective unexposed, disease free excluded Adjustment: No extrapolated (cont. endpoint) Matched Monotherapy: no or not specified 1.64 [1.08;2.50]
excluded (control group) 		-/128   -/167 - 128
ref
S14999
R61400		 Olstad - (Es)citalopram (Controls unexposed, sick), 2023 Attention deficit hyperactivity disorder (ADHD) assessment - CBCL-DSM (ADHD subscale)— 5 years during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: No extrapolated (cont. endpoint) Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 0.59 [0.37;0.95] -/128   -/102 - 128
ref
Total 1 studies 0.59 [0.37;0.95] 0 128
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Olstad - (Es)citalopram (Controls unexposed, sick), 2023Olstad -, 2023 1 0.59[0.37; 0.95]-1280%ROB confusion: seriousROB selection: unclearROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Es)citalopram (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 Tags Adjustment   - No  - No 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 Monotherapy   - no or not specified  - no or not specified 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 Unexposed sick   - recent illness/treatment (during o ...  - recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 1 All studiesAll studies 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 14998

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.64[1.08; 2.50]-128 -NAOlstad - (Es)citalopram (Controls unexposed, disease free), 2023 1 unexposed, sick controlsunexposed, sick controls 0.59[0.37; 0.95]-128 -NAOlstad - (Es)citalopram (Controls unexposed, sick), 2023 10.510.01.0